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Implications for Nursing Care Introduction 
From the end of 2019 until present and 
into the foreseeable future, SARS-CoV-2, Underlying 
or Coronavirus disease 2019 (COVID-
19), has been in the forefront of our Pathophysiology 
concerns. Having a novel virus at the 
root of a pandemic, limited information There are a several coagulation 
is available, especially initially, on the abnormalities that have been revealed in 
scope of the signs and symptoms, individuals diagnosed with COVID-19. 
effective treatment, and the extent of the As with many infections or 
lasting effects, as well as the many other inflammatory responses, a 
aspects involved with this illness. As hypercoagulable state can emerge. 
time has passed, it has been realized that These are familiarly classified under 
the virus leaves many in a Virchow’s Triad: 
hypercoagulable state (Abou-Ismail et 
al., 2020). 1. Injury to vessel endothelium – 
research shows that the virus 
To effectively treat those afflicted with directly attacks endothelial cells. 
this specific symptom of COVID-19, an Endothelialitis is a significant 
understanding of the pathophysiology of contributor to thrombosis 
the virus must be established to formation. 
effectively treat and potentially prevent 
coagulopathy and the thrombotic events 2. Abnormalities of Blood Flow, or 
that can ensue. Gaining more insight into Stasis – for most patients with 
this will allow for standardized plan of COVID-19, this is in direct 
care that includes appropriate response to decreased mobility 
predicative labs and effective in light of the extenuating 
prophylactic medications to be utilized symptoms of the virus, especially 
in outpatient or inpatient settings to with hospitalized individuals. 
prevent a hypercoagulable state from 
occurring or minimize the medical 3. Hypercoagulability of the Blood – 
effects of a thrombotic event. this is caused by the 
inflammatory state of the virus or 
infection. 




“The novel SARS-CoV-2 appears to 
generate a profoundly prothrombotic 
milieu as evidenced by a surge in global 
reports of arterial, venous and catheter-
related thrombosis (Abou-Ismail et al., 
2020). While there are similarities shared 
with other viruses and responses, there 
are several points of distinction with the 
hypercoagulable state seen with  COVID-
19.: 
• Venous Thromnoembolism -
Pulmonary embolism (PE) is the most 
common expression.  Post-mortem 
examinations have consistently 
revealed PE’s and microthrombi in 
alveolar capillaries. . (Abou-Ismail et 
al., 2020) Deep Vein Thrombosis 
(DVT)  are commonly seen as well 
and have been found to impact the 
bilateral lower extremities. 
• Stroke – Ischemic strokes have been 
seen as the typical manifestation, 
along with limb ischemia, both of 
which are more noted in large 
vessels. 
• The spike protein found on SARS-
CoV-2 has been linked to activating a 
dysregulated alternative complement 
pathway, causing a cytokine storm. 
• The spike protein found on SARS-
CoV-2 has been linked to a 
derangement in the Renin-
Angiotensin-Aldosterone pathway, 
which contributes to the 
hypercogulable state. 
Figure B. Pathophysiology of the Hypercoagulable State in COVID-19. The current 
understanding of the pathophysiology of COVID-19 induced coagulopathy centers 
around the bidirectional cross-talk between inflammation (yellow arrows) and 
thrombosis (black arrows). COVID-19 leads to a severe inflammatory response 
that originates in the alveoli. Release of inflammatory cytokines leads to 
activation of epithelial cells, monocytes and macrophages. Direct infection of the 
endothelial cells through the ACE2 receptor also leads to endothelial activation 
and dysfunction,, all of which contribute to thrombin generation and fibrin clot 
formation. Thrombin, in turn, causes inflammation through its effect on platelets 
which promote NET formation in neutrophils. It also activates endothelium 
through the PAR receptor, which leads to release of C5A that further activates 
monocytes. These mechanisms are currently hypothetical based on existing 
findings in COVID-19 and previous understanding of the cross-talk between 
inflammation and thrombosis. ACE2: Angiotensin-converting enzyme 2. FVIII: 
Factor VIII. IL: Interleukin. NET: Neutrophil extracellular trap. TF: Tissue factor. 
TNF: Tumor necrosis factor. VWF: von Willebrand factor. (Abou-Ismail et al., 
2020) 
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Monitoring cogualation abnormalities 
via serum laboratory testing has been a 
key indicator in determining 
hypercoagulable diagnoses.  The 
standard set of test to offer the most 
insight are: 
• Abnormal or slightly prolonged 
Prothrombin Time AND aPTT 
• Platelet counts normal or slightly 
increased. 
• Fibrinogen increased 
• D-Dimer increased. 
Along with any of these abnormalities, in 
order to definitely detect and diagnoses a 
hypercoagulable manifestation, 
ultrasound imaging has been found to 
offer the most insight in locating the 
impacted area of a DVT, while a CT is 
used to confirm a PE. 
Once a confirmation of a thrombotic 
event has been made, there are several 
courses of treatment that can be 
administered to effectively mitigate the 
situation. The most common and most 
effective are: 
• Low-Molecular Weight Heparin at a 
moderate to full-dose 
• Tissue Plasminogen Activator in 
cases of a massive and/or 
obstructive PE, Central-line 
associated thrombosis, limb-
threatening DVT or acute stroke. 
Conclusions 
Though the research is technically incomplete at this time due to the novelty of the 
virus, there is reliable and valuable information available to be extracted, applied and 
utilized in the clinical setting to mitigate the mortality risk of patients diagnosed with 
COVID-19. 
Understanding the causative factors in the pathophysiological process of the 
hypercoagulable state allows for more strategic management of patients’ conditions. 
Insight is given into serum laboratory tests to monitor, imaging to perform and 
therapeutic medicinal management to implement.  These interventional strategies 
allow clinicians an opportunity to prevent further complications of the virus for their 
patients. 
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